As a selective inhibitor of the PI3K catalytic subunit δ, idelalisib was the first PI3K inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) in combination with rituximab. The gene discussed is PIK3CA; the disease is B-cell chronic lymphocytic leukemia.